{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:33:29Z","timestamp":1783971209243,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"Background<\/jats:title>Management of coronary artery disease (CAD) is unique and challenging in cancer patients. However, little is known about the outcomes of using BMS or DES in these patients. This study aimed to compare the outcomes of percutaneous coronary intervention (PCI) in cancer patients who were treated with bare metal stents (BMS) vs. drug-eluting stents (DES).<\/jats:p><\/jats:sec>Methods<\/jats:title>We identified cancer patients who underwent PCI using BMS or DES between 2013 and 2020. Outcomes of interest were overall survival (OS) and the number of revascularizations. The Kaplan\u2013Meier method was used to estimate the survival probability. Multivariate Cox regression models were utilized to compare OS between BMS and DES.<\/jats:p><\/jats:sec>Results<\/jats:title>We included 346 cancer patients who underwent PCI with a median follow-up of 34.1 months (95% CI, 28.4\u201338.7). Among these, 42 patients were treated with BMS (12.1%) and 304 with DES (87.9%). Age and gender were similar between the BMS and DES groups (p<\/jats:italic> = 0.09 and 0.93, respectively). DES use was more frequent in the white race, while black patients had more BMS (p<\/jats:italic> = 0.03). The use of DES was more common in patients with NSTEMI (p<\/jats:italic> = 0.03). The median survival was 46 months (95% CI, 34\u201366). There was no significant difference in the number of revascularizations between the BMS and DES groups (p<\/jats:italic> = 0.43). There was no significant difference in OS between the BMS and DES groups in multivariate analysis (p<\/jats:italic> = 0.26). In addition, independent predictors for worse survival included age &gt; 65 years, BMI \u2264 25 g\/m2<\/jats:sup>, hemoglobin level \u2264 12 g\/dL, and initial presentation with NSTEMI.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In our study, several revascularizations and survival were similar between cancer patients with CAD treated with BMS and DES. This finding suggests that DES use is not associated with an increased risk for stent thrombosis, and as cancer survival improves, there may be a more significant role for DES.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.901431","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T04:40:58Z","timestamp":1666154458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents"],"prefix":"10.3389","volume":"9","author":[{"given":"Talha","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homam Moussa","family":"Pacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Addoumieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Charitakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos Dean","family":"Boudoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Cilingiroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Marmagkiolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Grines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar A.","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2017-05-743187","article-title":"Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents","volume":"131","author":"Xu","year":"2018","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12872-020-01352-0","article-title":"Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and\/or percutaneous coronary intervention","volume":"20","author":"Roule","year":"2020","journal-title":"BMC Cardiovasc Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.ijcard.2012.11.009","article-title":"Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients","volume":"167","author":"Kurisu","year":"2013","journal-title":"Int J Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MCA.0000000000000429","article-title":"Long-term outcomes after percutaneous coronary interventions in cancer survivors","volume":"28","author":"Landes","year":"2017","journal-title":"Coron Artery Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.mayocp.2016.06.029","article-title":"Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction","volume":"91","author":"Wang","year":"2016","journal-title":"Mayo Clin Proc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","article-title":"Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States","volume":"40","author":"Potts","year":"2019","journal-title":"Eur Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ccd.28045","article-title":"Meta-analysis of drug eluting stents compared with bare metal stents in high bleeding risk patients undergoing percutaneous coronary interventions","volume":"94","author":"Neupane","year":"2019","journal-title":"Catheter Cardiovasc Interv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/MCA.0000000000000986","article-title":"Cancer treatment resumption in patients with new-generation drug-eluting stents","volume":"32","author":"Balanescu","year":"2021","journal-title":"Coron Artery Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e001779","DOI":"10.1161\/JAHA.115.001779","article-title":"Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention","volume":"4","author":"Hess","year":"2015","journal-title":"J Am Heart Assoc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"JACC Cardio Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/ccd.26379","article-title":"SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/bjc.2014.491","article-title":"Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer","volume":"111","author":"Ramcharan","year":"2014","journal-title":"Br J Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"665303","DOI":"10.3389\/fcvm.2021.665303","article-title":"Coronary stent healing in cancer patients-an optical coherence tomography perspective","volume":"8","author":"Aziz","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00380-021-01817-y","article-title":"Temporal trends in short and long-term outcomes after percutaneous coronary interventions among cancer patients","volume":"36","author":"Nardi Agmon","year":"2021","journal-title":"Heart Vessels."},{"key":"B17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijcard.2019.09.016","article-title":"Outcomes following percutaneous coronary intervention in patients with cancer","volume":"300","author":"Quintana","year":"2020","journal-title":"Int J Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"One-month DAPT investigators","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2021.08.074","article-title":"Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI","volume":"78","author":"Valgimigli","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1161\/CIR.0000000000001039","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e009565","DOI":"10.1161\/CIRCINTERVENTIONS.120.009565","article-title":"One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients","volume":"13","author":"Kandzari","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Cardiol Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ccd.28798","article-title":"Italian multicenter registry of bare metal stent use in modern percutaneous coronary intervention era (AMARCORD): a multicenter observational study","volume":"97","author":"Giannini","year":"2021","journal-title":"Catheter Cardiovasc Interv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2017.02.091","article-title":"The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: a meta-analysis of randomized trials","volume":"235","author":"Wang","year":"2017","journal-title":"Int J Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e010144","DOI":"10.1161\/CIRCINTERVENTIONS.120.010144","article-title":"Primary results of the EVOLVE short DAPT study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent","volume":"14","author":"Kirtane","year":"2021","journal-title":"Circ Cardiovasc Interv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.jcin.2016.07.021","article-title":"Effects of Intravascular ultrasound-guided versus angiography-guided new-generation drug-eluting stent implantation: meta-analysis with individual patient-level data from 2,345 randomized patients","volume":"9","author":"Shin","year":"2016","journal-title":"JACC Cardiovasc Interv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1016\/j.jacc.2018.09.013","article-title":"Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ULTIMATE trial","volume":"72","author":"Zhang","year":"2018","journal-title":"J Am Coll Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.901431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T04:41:00Z","timestamp":1666154460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.901431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":30,"alternative-id":["10.3389\/fcvm.2022.901431"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.901431","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"article-number":"901431"}}